ArticleAvicenna journal of phytomedicine2026
Multi-target healing mechanisms of
Article in Avicenna journal of phytomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This research investigated the multi-target mechanisms of Materials and Methods: The bioactive compounds of HL leaves' 70% ethanol extract were detected using liquid chromatography-high-resolution mass spectrometry (LC-HRMS), and potential targets were predicted via the SwissTargetPrediction. Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses were conducted using DAVID. Molecular docking was predicted using MOE version 2015.10. In vitro assays using HaCaT cells evaluated proliferation and Tumor Necrosis Factor-alpha (TNF-α) levels via ELISA. In vivo measurement in diabetic rats induced by streptozotocin (n = 9 per group), with histopathological analysis conducted on days 7, 14, and 21. Results: HL extract exhibited anti-inflammatory and pro-proliferative effects, primarily mediated by syringic acid (P41) and vanillactic acid (P43). These compounds upregulated AKT1, MAPK3, and HIF-1α. HL treatment significantly enhanced HaCaT cell proliferation (p < 0.0001) and reduced TNF-α level at 31.25 ppm (p < 0.05). In vivo, HL treatment decreased inflammatory cell infiltration from day 7, with significant tissue regeneration observed by day 14 (p < 0.01) relative to base control. Conclusion: HL and its bioactive constituents demonstrate promising potential for diabetic wound healing by modulating inflammatory mediators (TNF-α) and enhancing key regenerative pathways (AKT1, MAPK3, and HIF-1α).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.